Lacosamid Teva

Lacosamide, the active ingredient in Lacosamid Teva, is an anti‑epileptic drug presented as an oral formulation for oral use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency when added to existing treatment regimens.

GNH USA supplies Lacosamid Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is used in the management of seizure disorders, specifically targeting focal epileptic activity. - Partial‑onset seizures: reduces seizure frequency when used as adjunctive therapy. - Focal seizures: improves control of seizure episodes in refractory cases. - Adjunctive therapy in refractory epilepsy: provides additional seizure reduction when other agents are insufficient.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired or low in energy. - Nausea: mild to moderate stomach upset. - Headache: occasional mild to moderate pain. - Diplopia: temporary double vision. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Suicidal ideation: thoughts of self‑harm requiring immediate evaluation. - Cardiac conduction abnormalities: PR‑interval prolongation that may lead to arrhythmia. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Anaphylaxis: severe allergic response. - Blood dyscrasias: rare cases of agranulocytosis or thrombocytopenia.

When prescribing Lacosamide, clinicians should consider several safety aspects. - Renal impairment: dose may need adjustment and renal function monitoring. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction: obtain baseline ECG and monitor for PR‑interval changes. - Pregnancy: risk unknown; use only if potential benefit justifies the risk. - Concomitant CNS depressants: may increase sedation; observe patient response. - Store at ambient temperature: keep in original packaging, protect from moisture and excessive heat.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, reducing lacosamide plasma levels. - Phenytoin: strong enzyme inducer that lowers lacosamide concentrations. - Strong CYP3A4 inducers (e.g., rifampin): may decrease therapeutic effect.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation and dizziness. - Alcohol: can increase central nervous system effects. - Other anti‑epileptic drugs: monitor seizure control and adjust doses as needed.